Ironshore Pharmaceuticals Inc. Sustainability Profile
Ironshore Pharmaceuticals Inc., headquartered in Kentucky, is a prominent player in the pharmaceutical industry, specialising in the development of innovative treatments for rare diseases. Founded in 2012, the company has made significant strides in addressing unmet medical needs, particularly in the areas of neurology and psychiatry. Ironshore's core products include unique formulations that enhance drug delivery and patient compliance, setting them apart in a competitive market. With a focus on precision medicine, Ironshore has established a strong market position, recognised for its commitment to research and development. The company continues to expand its operational footprint, aiming to improve the lives of patients globally through its specialised therapies.
DitchCarbon Score
How does Ironshore Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ironshore Pharmaceuticals Inc.'s score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ironshore Pharmaceuticals Inc.'s reported carbon emissions
Ironshore Pharmaceuticals Inc., headquartered in Kentucky (KY), currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Collegium Pharmaceutical, Inc., which may influence its climate commitments and reporting practices. As of now, Ironshore Pharmaceuticals has not established any documented reduction targets or climate pledges. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction, it is likely that Ironshore Pharmaceuticals will need to align with industry standards and expectations regarding emissions reporting and climate action in the future.
How Carbon Intensive is Ironshore Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Ironshore Pharmaceuticals Inc.'s Location?
Ironshore Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ironshore Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
